Phase 2 window study of SAR439859 (amcenestrant) versus letrozole in post-menopausal patients with ER+, HER2- pre-operative post-menopausal primary breast cancer

Trial Identifier: ACT16106
Sponsor: sanofi
Start Date: February 2020
Primary Completion Date: April 2021
Study Completion Date: May 2021
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
BELGIUM Leuven, BELGIUM, 3000
BELGIUM Namur, BELGIUM, 5000
FRANCE Nantes, FRANCE, 44093
FRANCE Paris, FRANCE, 75010
FRANCE Saint Cloud, FRANCE, 92210
FRANCE Toulouse Cedex 9, FRANCE, 31059
ITALY Meldola, ITALY, 47014
ITALY Milano, ITALY, 20141
ITALY Milano, ITALY, 20132
JAPAN Osaka-Shi, JAPAN
JAPAN Sapporo-Shi, JAPAN
JAPAN Yokohama-Shi, JAPAN
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 119991
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 117186
RUSSIAN FEDERATION Saint -Petersburg, RUSSIAN FEDERATION, 197758
RUSSIAN FEDERATION Saint-Petersburg, RUSSIAN FEDERATION, 194156
RUSSIAN FEDERATION St.Petersburg, RUSSIAN FEDERATION, 195271
SPAIN Barcelona, SPAIN, 08003
SPAIN Córdoba, SPAIN, 14004
SPAIN Madrid, SPAIN, 28041
SPAIN Valencia / Valencia, SPAIN, 46010
UKRAINE Kharkiv, UKRAINE, 61166
UKRAINE Uzhgorod, UKRAINE, 88000
UKRAINE Vinnytsia, UKRAINE, 21029
UKRAINE Zaporizhzhya, UKRAINE, 69040
UNITED STATES, Arizona Tucson, Arizona, UNITED STATES, 85724
UNITED STATES, California Los Angeles, California, UNITED STATES, 90095
UNITED STATES, Indiana Fort Wayne, Indiana, UNITED STATES, 46804
UNITED STATES, Nebraska Lincoln, Nebraska, UNITED STATES, 68506
UNITED STATES, North Carolina Winston Salem, North Carolina, UNITED STATES, 27157
UNITED STATES, Puerto Rico Hato Rey, Puerto Rico, UNITED STATES, 00917
UNITED STATES, Washington Tacoma, Washington, UNITED STATES, 98405